Evidence map›Paper›PMID 26923702›Full record

ArticleBreast cancer research : BCR2016

An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.

Karolina Holm, Johan Staaf, Martin Lauss, Mattias Aine, David Lindgren, Pär-Ola Bendahl, Johan Vallon-Christersson, Rosa Bjork Barkardottir, Mattias Höglund, Åke Borg and 2 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 104 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Karolina HolmDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. karolina.holm@med.lu.se.
Johan StaafDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. johan.staaf@med.lu.se.
Martin LaussDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. martin.lauss@med.lu.se.
Mattias AineDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. mattias.aine@med.lu.se.
David LindgrenDivision of Translational Cancer Research, Department of Laboratory Medicine Lund, Lund University, Lund, Sweden. david.lindgren@med.lu.se.
Pär-Ola BendahlDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. par-ola.bendahl@med.lu.se.
Johan Vallon-ChristerssonDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. johan.vallon-christersson@med.lu.se.
Rosa Bjork BarkardottirDepartment of Pathology, Landspitali-University Hospital, Reykjavik, Iceland. rosa@landspitali.is.
Mattias HöglundDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. mattias.hoglund@med.lu.se.
Åke BorgDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. ake.borg@med.lu.se.
Göran JönssonDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. goran_b.jonsson@med.lu.se.
Markus RingnérDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. markus.ringner@med.lu.se.
Lund University · SEReykjavík University · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant DNA methylation is frequently observed in breast cancer. However, the relationship between methylation patterns and the heterogeneity of breast cancer has not been comprehensively characterized.

methodsWhole-genome DNA methylation analysis using Illumina Infinium HumanMethylation450 BeadChip arrays was performed on 188 human breast tumors. Unsupervised bootstrap consensus clustering was performed to identify DNA methylation epigenetic subgroups (epitypes). The Cancer Genome Atlas data, including methylation profiles of 669 human breast tumors, was used for validation. The identified epitypes were characterized by integration with publicly available genome-wide data, including gene expression levels, DNA copy numbers, whole-exome sequencing data, and chromatin states.

resultsWe identified seven breast cancer epitypes. One epitype was distinctly associated with basal-like tumors and with BRCA1 mutations, one epitype contained a subset of ERBB2-amplified tumors characterized by multiple additional amplifications and the most complex genomes, and one epitype displayed a methylation profile similar to normal epithelial cells. Luminal tumors were stratified into the remaining four epitypes, with differences in promoter hypermethylation, global hypomethylation, proliferative rates, and genomic instability. Specific hyper- and hypomethylation across the basal-like epitype was rare. However, we observed that the candidate genomic instability drivers BRCA1 and HORMAD1 displayed aberrant methylation linked to gene expression levels in some basal-like tumors. Hypomethylation in luminal tumors was associated with DNA repeats and subtelomeric regions. We observed two dominant patterns of aberrant methylation in breast cancer. One pattern, constitutively methylated in both basal-like and luminal breast cancer, was linked to genes with promoters in a Polycomb-repressed state in normal epithelial cells and displayed no correlation with gene expression levels. The second pattern correlated with gene expression levels and was associated with methylation in luminal tumors and genes with active promoters in normal epithelial cells.

conclusionsOur results suggest that hypermethylation patterns across basal-like breast cancer may have limited influence on tumor progression and instead reflect the repressed chromatin state of the tissue of origin. On the contrary, hypermethylation patterns specific to luminal breast cancer influence gene expression, may contribute to tumor progression, and may present an actionable epigenetic alteration in a subset of luminal breast cancers.

Indexed as

Breast NeoplasmsCell Line, TumorChromatinCpG IslandsDNA MethylationEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticGenome, HumanHumansMammary Glands, HumanNeoplasm ProteinsOligonucleotide Array Sequence AnalysisPromoter Regions, GeneticChromatinNeoplasm Proteins

Identifiers

PMID26923702
PMCPMC4770527
OpenAlexW2292247613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.